Glucometer versus analyzer: comparable results with negligible clinical risk

Area of Science:

• Clinical Chemistry
• Medical Device Technology
• Diabetes Management

Background:

• Accurate blood glucose monitoring is crucial for diabetes management.
• Point-of-care glucose meters are widely used but require validation in real-world clinical settings.
• Assessing the reliability of widely adopted devices like the Roche Accu-Chek Inform II is essential for patient safety and effective treatment.

Purpose of the Study:

• To evaluate the real-world reliability and accuracy of Roche Accu-Chek Inform II glucometers.
• To compare glucometer results against a laboratory reference method using established guidelines.
• To identify areas for potential improvement in glucometer performance.

Main Methods:

• Retrospective analysis of 6,695 paired capillary and venous blood glucose results.
• Comparison of Roche Accu-Chek Inform II (capillary) with Roche Cobas analyzers (venous).
• Assessment of compliance using modified ISO 15197 and CLSI EP09-A3 criteria, including Passing-Bablok regression, Bland-Altman plots, and Surveillance Error Grid (SEG) analysis.

Main Results:

• Overall compliance was 81.5%, below the 94.6% acceptance criterion.
• SEG analysis indicated 90.3% of results were in the 'No-risk' zone.
• A small positive bias (0.33 mmol/L) was observed, with mean differences within permissible limits according to Bland-Altman analysis.
• Compliance varied by concentration, with highest accuracy observed between 16.65-22.20 mmol/L.

Conclusions:

• Roche Accu-Chek Inform II glucometers demonstrate real-world reliability with most results in acceptable risk categories.
• While generally reliable, the overall compliance rate indicates a need for manufacturers to explore advancements for improved accuracy.
• Further optimization could enhance the clinical utility of these point-of-care devices for diabetes management.